Peptides have been a staple of the beauty industry for more than two decades.
They did not need a rebrand or a trend cycle. The ingredient works quietly, reliably, across formulations for everything from skin barrier repair to anti-ageing, long before social media algorithms decided it had “main character energy”.
But with the US Food and Drug Administration (FDA) convening a two-day review of several key peptides this July [23 to 24 July], what does it mean for the beauty brands that have built product lines and customer trust around them?
Have you launched an innovative product, brand or campaign in the past 12 months? Then you could be in with a chance of winning at this year's new and improved Pure Beauty Awards 2026. Click here for more information.
The short answer: this moment matters more than most brands realise.
The longer answer requires understanding what is actually driving the regulatory conversation and what the beauty industry should do about it.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Cosmetics Business.
Subscribe now Already a subscriber? Sign in here.
